

1 CHAD A. READLER  
 Acting Assistant Attorney General  
 2 GUSTAV W. EYLER  
 Acting Director  
 3 Consumer Protection Branch  
 NATALIE N. SANDERS  
 4 Trial Attorney  
 Consumer Protection Branch  
 5 U.S. Department of Justice  
 450 5th Street, NW, Suite 6400-South  
 6 Washington, D.C. 20530  
 Telephone: (202) 598-2208  
 7 Facsimile: (202) 514-8742  
 E-mail: Natalie.N.Sanders@usdoj.gov

8 Attorneys for Plaintiff  
 9 UNITED STATES OF AMERICA

10 UNITED STATES DISTRICT COURT  
 11 FOR THE CENTRAL DISTRICT OF CALIFORNIA  
 12 EASTERN DIVISION

14 UNITED STATES OF AMERICA,  
 15 Plaintiff,  
 16 v.  
 17 CALIFORNIA STEM CELL  
 18 TREATMENT CENTER, INC., et al.,  
 19 Defendants.

No. 5:18-CV-01005-JGB-KKx

**JOINT RULE 26(f) REPORT**

Sched. Conf.: October 1, 2018 at 11:00 AM

Hon. Judge Jesus G. Bernal  
 Riverside, Courtroom 1

21  
 22  
 23 Plaintiff, the United States of America, and Defendants California Stem Cell  
 24 Treatment Center, Inc. (“CSCTC”), Cell Surgical Network Corporation (“CSN”), Elliot  
 25 B. Lander, M.D. (“Lander”), and Mark Berman, M.D. (“Berman”), by and through  
 26 undersigned counsel and pursuant to Federal Rule of Civil Procedure 26(f), Local Rule  
 27 26-1, and this Court’s July 18, 2018 Order Setting Scheduling Conference (D.E. 28),  
 28 hereby file their joint scheduling report addressing discovery and other pretrial issues.

1 Pursuant to Federal Rule of Civil Procedure 26(f) and Local Rule 26-1, the  
2 following attorneys appeared telephonically to meet and confer on September 10, 2018,  
3 at 1:00 P.M. PT: undersigned counsel for the United States and Defendants’ counsel Mr.  
4 Chang. Additional planning telephone conferences took place on July 2, 2018, and  
5 August 29, 2018, between aforementioned counsel. The Parties have conferred in order  
6 to present jointly this Joint 26(f) Report addressing each of the items set forth in this  
7 Court’s July 18, 2018 Order Setting Scheduling Conference.

8 **A. Statement of the Case**

9 The United States claims that Defendants manufacture, or have caused to be  
10 manufactured, the following adipose (fat) derived products (“CSCTC products”): (1) a  
11 “stromal vascular fraction” product (the “SVF product”) manufactured from a patient’s  
12 adipose tissue; (2) a product that combines SVF and Vaccinia Vaccine, Live (the  
13 “SVF/Vaccinia product”); and (3) a product containing SVF that has been expanded in  
14 culture by a third party (the “expanded SVF product”), and that all such CSCTC  
15 products are intended for use in the treatment, cure, or mitigation of various diseases and  
16 conditions for which the CSCTC products are not approved. The United States further  
17 contends that Defendants’ CSCTC products are subject to regulation under the Federal  
18 Food, Drug, and Cosmetic Act (“FDCA”), including the FDCA’s adulteration and  
19 misbranding provisions and the FDCA’s Current Good Manufacturing Practice  
20 (“CGMP”) regulations.

21 Defendants contend that they do not manufacture “products,” but rather they  
22 conduct SVF procedures (“SVF procedures”) which are not subject to regulation by the  
23 U.S. Food and Drug Administration (“FDA”). Defendants contend that FDA lacks  
24 jurisdiction under the FDCA and the U.S. Constitution to regulate Defendants’ SVF  
25 procedures, and that the SVF procedures are exempt from regulation through the  
26 operation of either 21 C.F.R. § 1271.10(a) or the “same surgical procedure exception” of  
27 21 C.F.R. § 1271.15(b).

1 The United States brings this statutory injunction proceeding pursuant to the  
2 FDCA, 21 U.S.C. § 332(a), to enjoin Defendants from (1) violating 21 U.S.C. § 331(k)  
3 by causing articles of drug to become adulterated within the meaning of 21 U.S.C.  
4 § 351(a)(2)(B), and misbranded within the meaning of 21 U.S.C. §§ 352(f)(1), 352(j),  
5 and 353(b)(4), while held for sale after shipment of the drugs or one or more of their  
6 components in interstate commerce, and from (2) violating 21 U.S.C. § 331(c) by  
7 receiving misbranded drugs in interstate commerce and delivering or proffering for  
8 delivery such drugs for pay or otherwise.

9 The United States also seeks that FDA be authorized to inspect Defendants' places  
10 of business and all records relating to the receipt, manufacture, processing, packing,  
11 labeling, holding, and distribution of any drug and/or drug component to ensure  
12 continuing compliance with the terms of the injunction, with the costs of such  
13 inspections to be borne by Defendants, as well as costs and other such relief as the Court  
14 deems just and proper, including equitable monetary relief.

15 **B. Subject Matter Jurisdiction**

16 In the United States' view, the basis for the Court's subject matter jurisdiction is  
17 21 U.S.C. § 332(a), which authorizes the Court to restrain violations of § 331(c) and (k)  
18 of the FDCA. The Court also has jurisdiction over this action pursuant to 28 U.S.C. §§  
19 1331 (federal question), 1337 (commerce), and 1345 (U.S. as plaintiff).

20 Defendants contest the Court's jurisdiction and have raised the lack of subject  
21 matter jurisdiction as an affirmative defense in their Answer. More specifically, and as  
22 stated above, Defendants contend that FDA and this Court lack jurisdiction under the  
23 FDCA and the U.S. Constitution to regulate Defendants' SVF procedures.

24 **C. Legal Issues**

25 Based on the Complaint and Defendants' Answer, the issues as presently known  
26 to the Parties are as follows:  
27  
28

- 1 a. Whether the Defendants’ purported practices involve “drugs” within the  
2 meaning of the FDCA, 21 U.S.C. § 321(g)(1)(B), (C), and relevant  
3 regulations, 21 C.F.R. § 201.128;
- 4 b. Whether the Defendants’ purported practices involve “prescription drugs”  
5 within the meaning of the FDCA, 21 U.S.C. § 353(b)(1)(A);
- 6 c. Whether the Defendants’ purported practices involve “new drugs” within  
7 the meaning of the FDCA, 21 U.S.C. § 321(p)(1) and/or 21 U.S.C. §  
8 321(p)(2);
- 9 d. Whether the Defendants’ purported practices involve “biological products”  
10 within the meaning of the Public Health Service Act (“PHSA”), 42 U.S.C. §  
11 262(i);
- 12 e. Whether the Defendants’ purported practices involve “human cells, tissues,  
13 or cellular or tissue-based products” (“HCT/Ps”), defined as “articles  
14 containing or consisting of human cells or tissues that are intended for  
15 implantation, transplantation, infusion, or transfer into a human recipient.”  
16 21 C.F.R. § 1271.3(d);
- 17 f. Whether the Defendants’ CSCTC products/SVF procedures qualify for the  
18 “same surgical procedure exception” in 21 C.F.R. § 1271.15(b);
- 19 g. Whether the Defendants’ CSCTC products/SVF procedures meet all of the  
20 criteria in 21 C.F.R. § 1271.10(a) for regulation solely under the PHSA and  
21 21 C.F.R. Part 1271;
- 22 h. Whether the FDA lacks jurisdiction under the FDCA, the U.S. Constitution,  
23 or otherwise to regulate Defendants’ CSCTC products/SVF procedures.
- 24 i. Whether the Defendants’ purported practices use methods, facilities, and  
25 controls that conform to CGMP. *See* 21 U.S.C. § 351(a)(2)(B) and 21  
26 C.F.R. Parts 210-211; *see also* 21 C.F.R. Parts 600-680 (setting forth  
27 additional standards and manufacturing requirements applicable to  
28 biological products);

- j. Whether the Defendants' CSCTC products, as alleged in the Complaint, are adulterated within the meaning of the FDCA, 21 U.S.C. § 351(a)(2)(B), or misbranded within the meaning of the FDCA, 21 U.S.C. § 352(f)(1) or 353(b)(4);
- k. Whether the Defendants' SVF/Vaccinia product, as alleged in the Complaint, is misbranded within the meaning of the FDCA, 21 U.S.C. § 352(j);
- l. Whether Defendants violate 21 U.S.C. § 331(k) by causing the adulteration of CSCTC products within the meaning of 21 U.S.C. § 351(a)(2)(B);
- m. Whether Defendants violate 21 U.S.C. § 331(k) by causing the misbranding of CSCTC products within the meaning of 21 U.S.C. § 352(f)(1), 352(j), and 353(b)(4); and
- n. Whether Defendants violate 21 U.S.C. § 331(c) by receiving in interstate commerce and delivering or proffering for delivery drugs that are misbranded within the meaning of 21 U.S.C. §§ 352(f)(1) and 353(b)(4);

**D. Parties, Evidence, etc.**

Parties

Plaintiff – United States

Defendants – CSCTC, CSN, Lander, and Berman

Plaintiff's Evidence

In addition to the witnesses and documents identified by the Defendants, the United States identifies the following witnesses and documents. Additional witnesses and documents may come to light upon discovery and the United States reserves the right to make revisions.

Witnesses

1. Karlton Watson, Program Division Director
2. Catherine Quinlan, Director of Compliance Branch
3. Sam Labinjo, Compliance Officer

- 1 4. Daniel Cline, Compliance Officer
- 2 5. Randall Morris, Compliance Officer
- 3 6. William Frederick Lagud, Jr., Consumer Safety Officer
- 4 7. Cynthia Jim, Consumer Safety Officer
- 5 8. Darla J. Christopher, Consumer Safety Officer
- 6 9. Michele L. Forster, Consumer Safety Officer
- 7 10.Kip Hanks, Consumer Safety Officer
- 8 11.Cody Rickman, Consumer Safety Officer
- 9 12.Christopher C. Joneckis, PhD, Associate Director for Review Management
- 10 13.Shawntae Dowell, Surgical Technologist
- 11 14.Brittany White, Surgical Technologist
- 12 15.Judi E. Meglio, Office Manager
- 13 16.Audrey Fianza, Certified Scrub/Surgical Technologist

14 *Key Documents*

- 15 1. Inspectional Observations (“Forms FDA 483”)
- 16 2. Establishment Inspection Reports (“EIRs”)
- 17 3. FDA Sample Collection Reports
- 18 4. Consumer Complaints
- 19 5. Published Articles
- 20 6. Files downloaded from the internet
- 21 7. Correspondence between FDA and Defendants

22 *Defendants’ Evidence*

23 In addition to the witnesses and documents identified by the United States,  
24 Defendants identify the following additional witnesses and documents in this action.  
25 Additional witnesses and documents may come to light upon discovery and Defendants  
26 reserve the right to make revisions.

27 *Witnesses*

- 28 1. Defendant Berman

2. Defendant Lander
3. Sean Berman
4. CSCTC and CSN patients

*Key Documents*

1. FDA statements regarding the pertinent regulatory scheme, including the Same Surgical Procedure Exemption
2. Communications between FDA and Defendants
3. Non-privileged internal FDA communications about Defendants
4. Non-privileged internal FDA communications about SVF procedures
5. Scientific articles regarding the Defendants' SVF procedures
6. Documents describing the Defendants' SVF procedures

**E. Damages**

Not applicable.

**F. Insurance**

Not applicable.

**G. Motions**

The Parties do not anticipate filing any motions to add parties or claims, amend the pleadings, or transfer venue at this time, but may seek leave to do so depending on the results of discovery.

**H. Manual for Complex Litigation**

The Parties agree that this is not a matter requiring the Manual for Complex Litigation.

**I. Status of Discovery**

The Parties have satisfied their meet and confer obligations under Federal Rule of Civil Procedure 26(f), Local Rule 26-1, and this Court's July 18, 2018 Order Setting Scheduling Conference.

The Parties will exchange their Rule 26(a) Initial Disclosures on September 24, 2018. Due to the breadth and scope of this case, both Parties reasonably expect that

1 supplemental disclosures may have to be made pursuant to Federal Rule of Civil  
2 Procedure 26(e).

3 The Parties intend to propound requests for admission and interrogatories on the  
4 topics outlined in section C above, with responses due within thirty (30) days of service.

5 Additionally, the Parties continue to work towards a set of facts that can be  
6 stipulated to without discovery.

7 **J. Discovery Plan**

8 Proposed Changes to Rule 26(a) Disclosures

9 The Parties agree that no changes to the disclosures under Federal Rule of Civil  
10 Procedure 26(a) are necessary. The Parties will exchange initial disclosures on  
11 September 24, 2018, and have agreed, consistent with their obligations under Federal  
12 Rule of Civil Procedure 26(e), to amend their disclosures as new information becomes  
13 available.

14 Discovery

15 Because the disputed matters in this case involve largely legal issues, the Parties  
16 agree that discovery should be conducted in phases in accordance with the schedule set  
17 forth below.

18 The Parties propose that the first phase of discovery will consist of the United  
19 States disclosing to Defendants documents and records related to FDA's inspections of  
20 Defendants' facilities that occurred between June 17 and June 27, 2017, as well as a  
21 round of interrogatories and requests for admission from each Party to the extent  
22 necessary to address material facts in dispute. Among other things, the Parties intend to  
23 propound interrogatories and requests for admission relating to the allegations in FDA's  
24 Complaint, Defendants' affirmative defenses, and the topics outlined in Section C above.  
25 The Parties believe that a limited phase of discovery should likely enable the Parties to  
26 fully brief dispositive motions for summary judgment framing the contested legal issues  
27 for the Court, while at the same time conserving the Parties' resources by not taking or  
28 defending depositions or responding to requests for production unnecessarily.

1 Out of an abundance of caution, however, the Parties propose an additional phase  
 2 of discovery involving depositions and requests for production, to the extent such is even  
 3 necessary to address genuine issues of fact remaining after the initial phase of discovery  
 4 is completed. The chart below outlines the Parties' discovery plan and what discovery  
 5 they intend to conduct at each phase of the discovery process:

<b>DEADLINE OR EVENT</b>	<b>AGREED DATE</b>
Phase 1 Discovery Begins (all claims and defenses) <ul style="list-style-type: none"> <li>• Requests for Admissions</li> <li>• Interrogatories</li> </ul>	September 14, 2018 (first day Requests for Admission and Interrogatories may be served)
Production to Defendants of documents and records related to FDA's inspection of Defendants' facilities that occurred between June 17 - 27, 2017	September 24, 2018
Last Date to Amend Pleadings or Add Parties without leave of Court	November 15, 2018
Deadline for completion of all Phase 1 discovery	December 17, 2018
Phase 2 Discovery Begins (remaining issues of material fact) <ul style="list-style-type: none"> <li>• Depositions (as needed)</li> <li>• Requests for Production (as needed)</li> </ul>	December 17, 2018 (first day Requests for Production and Deposition Notices may be served)
Disclosure of Expert Report(s) – initial	January 7, 2019
Disclosure of Expert Report(s) – rebuttal	February 6, 2019
Deadline for completion of all Phase 2 discovery (including hearing all discovery motions)	March 31, 2019

1	Last date to conduct settlement conference	April 30, 2019
2	Deadline to file all motions, including judgment motions,	May 31, 2019
3	motions related to summary judgment, and <i>Daubert</i> motions	
4	Deadline to argue/hear all non-discovery motions	June 24, 2019
5	Deadline to file all other trial-related motions, including	July 8, 2019
6	motions <i>in limine</i> directed towards trial evidence	
7	Deadline to file Memorandum of Contentions of Fact and	July 15, 2019
8	Law; Witness Lists; Joint Exhibit List; and Oppositions to	
9	motions in limine	
10	Deadline to file Proposed final pretrial conference order;	July 22, 2019
11	Proposed jury instructions, and any objections; Proposed	
12	verdict forms; and Statement of the case	

#### Electronically Stored Information

15 The Parties do not expect that there will be significant electronically stored  
16 information (“ESI”) relevant to the claims and defenses in this case. The Parties have  
17 engaged in discussions to develop a plan that is proportional and reasonable in relation to  
18 the nature of the complexity of the case, for the preservation, identification and  
19 production of the relevant ESI. See Parties’ Joint Plan for Discovery of Electronically  
20 Stored Information, attached as Exhibit B.

#### Claims of Privilege

22 In the event that discovery should need to proceed beyond the first phase of  
23 discovery, the United States anticipates filing a protective order shielding from discovery  
24 any agency documents or communications that are covered by any applicable privilege,  
25 including the deliberative process or law enforcement investigatory privileges. The  
26 Parties will confer in a good-faith effort to reach an agreed-upon protective order, which  
27 the Defendants reserve the right to contest.

1 The Parties agree to use the procedures set forth in Federal Rule of Civil  
2 Procedure 26(b)(5) to resolve any disputes regarding claims of privilege or protecting  
3 materials asserted as being for trial-preparation. The parties request that this proposed  
4 procedure be adopted within the Court's further orders.

5 **K. Discovery Cut-off**

6 See Schedule of Pretrial and Trial Dates, attached as Exhibit A.

7 **L. Expert Discovery**

8 See Exhibit A.

9 **M. Dispositive Motions**

10 Following sufficient discovery, the Parties expect to file motions for summary  
11 judgment or adjudication on some or all of their claims, as well as any motions *in limine*  
12 dictated by discovery. In particular, the Parties anticipate moving for summary  
13 judgment or partial summary judgement, in part, on the threshold legal question of  
14 whether FDA has authority under the FDCA and the Constitution to regulate  
15 Defendants' CSCTC products/SVF procedures.

16 **N. Settlement/Alternative Dispute Resolution**

17 The Parties have discussed settlement at length, including during in-person  
18 meetings attended by counsel for the Parties and for FDA on April 27, 2018, and on May  
19 8, 2018. Despite the Parties' good-faith attempts at settlement, a negotiated resolution  
20 does not appear likely prior to the Court's resolution of the threshold legal issues  
21 concerning the applicability of the FDCA to the Defendants' CSCTC products/SVF  
22 procedures. Thereafter, the Parties agree to utilize the Court Mediation Panel.

23 **O. Trial Estimate**

24 The Parties do not request a jury trial. The Parties expect the trial to take 5-7  
25 days. At this time, the United States contemplates calling 15 witnesses, and Defendants  
26 anticipate calling 15 witnesses. The Parties reserve the right to call additional witnesses.

1           **P.    Trial Counsel**

2           Trial counsel will include Natalie Sanders for the United States and Celeste Brecht  
3 and Witt Chang of Venable LLP for the Defendants.

4           **Q.    Independent Expert or Master**

5           At this time, the Parties agree that there is no need for an independent scientific  
6 expert or for a master pursuant to Rule 53, but the Parties respectfully request that a  
7 reference be available should a need arise.

8           **R.    Timetable**

9           See Exhibit A.

10          **S.    Other Issues**

11          As noted above, the Parties anticipate that limited discovery will enable the Parties  
12 to brief dispositive motions for summary judgment framing the threshold legal issues for  
13 the Court. In the event that discovery should need to proceed beyond the first phase of  
14 discovery, the United States on behalf of FDA anticipates filing a protective order for  
15 any depositions of FDA personnel not involved in the inspections of Defendants'  
16 facilities leading to the instant cause of action. The Parties will confer in a good-faith  
17 effort to determine whether such a protective order is necessary. Defendants expressly  
18 reserve all rights to contest the need or scope of such a protective order, and expressly  
19 reserve all rights to notice the deposition of any witness who may possess relevant  
20 knowledge. Similarly, the United States on behalf of the FDA would anticipate filing a  
21 protective order shielding from discovery any agency documents or communications that  
22 are covered by any applicable privilege, including the deliberative process or law  
23 enforcement investigatory privileges. The Parties will confer in a good-faith effort to  
24 determine whether such a protective order is necessary. Defendants expressly reserve all  
25 rights to contest the need or scope of such a protective order, and expressly reserve all  
26 rights to seek and compel the production of all relevant documents and communications.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

CHAD A. READLER  
United States Department of Justice  
Acting Assistant Attorney General  
Civil Division

GUSTAV W. EYLER  
Acting Director  
Consumer Protection Branch

/s/ Natalie N. Sanders  
NATALIE N. SANDERS  
Trial Attorney  
Consumer Protection Branch

Attorneys for Plaintiff  
UNITED STATES OF AMERICA

/s/ Witt W. Chang  
CELESTE M. BRECHT, Partner  
WITT W. CHANG, Associate  
Venable LLP

Attorneys for Defendants  
CALIFORNIA STELL CELL  
TREATMENT CENTER, INC.,  
et al.

All signatories listed on whose behalf this filing is submitted concur in the filing's content and have authorized the filing (L.R. 5-4.3.4(a)(2)(i)).

Exhibit A: Schedule of Pretrial and Trial Dates Worksheet

Exhibit B: Joint Plan for Discovery of Electronically Stored Information

**CERTIFICATE OF SERVICE**

I hereby certify that on this 17th day of September 2018, I electronically filed a true and correct copy of the foregoing JOINT RULE 26(F) REPORT through the Court's CM/ECF system, which will send a notice of electronic filing to the following:

Celeste M. Brecht  
Witt W. Chang  
VENABLE LLP

/s/ Natalie N. Sanders  
NATALIE N. SANDERS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28